1. Marketing Research Project
On
The Scope of Long Acting Injectable Pain Preparation and Survey of Current
Prescription Pattern of Injectables in Pain Management
A REPORT SUBMITTED
BY
MUNISH SHARDA
Rayat -Bahra Ropar Campus, Phagwara-Mohali Express Highway, Tehsil
Balachaur, Distt. S.B.S Nagar, Railmajra, Punjab 144533
SUBMITTED TO-Mr. Sudhanshu Narayan,Sr. Manager (AGM)
VENUS REMEDIES LTD.
http://www.venusremedies.com
51-52, Industrial area, Phase-1,Panchkula- 134113,Haryana India
Phone 91-172-2590113, Fax 91-172-2565566
2. ACKNOWLEDGEMENT
It is the great pleasure to take an opportunity to thanks various people who have helped
me through my training to complete my project work at Venus Remedies Limited . I am highly
grateful to my mentor Ms Ruhi Bagga (Deputy Product Manager) for inspiration and the
constructive suggestions that helped me in preparation of the project on “The Scope of Long
Acting Injectable Pain Preparation and Survey of Current Prescription Pattern of Injectable in
Pain Management”
I would like to show my gratitude to Miss Neha at Venus remedies limited for allowing
me to undergo for the training.
Finally, I would like to thanks Asst. Professor Mr. Sudhanshu Narain (AGM,PMT) who
helped me in coordinating my entire project and also to all those persons who took time out of
their busy schedule and answered our queries, without their encouraging guidance and
cooperation this project was unimaginable.
(MUNISH SHARDA)
3. DECLARATION
I hereby declare that the project work entitled “The Scope of Long Acting Injectable Pain
Preparation and Survey of Current Prescription Pattern of Injectable in Pain Management” IN
VENUS REMEDIES LIMITED is an authentic and original work carried out by me at Venus
remedies limited as per requirement of industrial training project for the award of Master of
Business Administration degree, under the esteemed guidance of
Mr. Sudhanshu Narain (AGM,PMT)
Place:
Date:
(Munish Sharda)
4. INDEX
Sr. No Title Page No.
1.
Company Profile 1-5
2.. Introduction of Pain 6-8
2. Objective of Study 9
3. Research Methodology 10-11
4. Data Analyses and Interpretation 12-44
Current Scenario of Injectable in Pain
Management (Mohali Area)
12-13
Current Scenario of Injectable in Pain
Management (Chandigarh Area)
14-15
Current Scenario of Injectable in Pain
Management (Nangal To Anandpur Sahib)
16-17
Doctor Prescription Pattern in Mohali 18
Doctor Prescription Pattern in Chandigarh 19
Doctor Prescription Pattern in Nangal 20
The Severity of Pain with which Patient come 21-26
Preferable Therapy given to them 27-34
Current Prescription Pattern of Injectable in Pain
Management ( Brand Wise)
35-36
Current Prescription Pattern of Injectable in Pain
Management (Ingredient Wise)
37-38
Class of Pain patient & Preferable Therapy given
to them
39-45
5. Conclusion 46
Annexure
- Reference
- - Questionnaire
-
I-II
5. COMPANY PROFILE
Mr. Pawan chaudhary (Chief Managing Director)
Mr. Peeyush Jain (Deputy. Managing Director)
Mrs. Manu Chaudhary ( Joint managing Director)
Mr. Ashutosh Jain (Executive Director)
VENUS REMEDIES LTD. Was incorporated as a private limited company on 15th day
September of 1989 in the name and style of Venus glucose Pvt. ltd, and subsequently converted
into a public company, 19th Sept. 1994 and the name was converted as “Venus Remedied ltd”
UNDER THE COMPANY ACT, issued by the register of companies, Punjab, Himachal Pradesh
and Chandigarh jalandhar. Company started production in the year 1991 with
intravenous/intramuscular (IV/IM) Injectable form at its running unit located at 52 Industrial
Area Phase-1, Panchukla Dist. Ambala (Haryana). In 1994 company produced eye/ear/nasal
product in the market company also certified as ‘WHO-GMP” (GOOD PRACTICE IN
MANUFACTURING AND QUALITY CONTROL), Geneva by the state Drug controller of
Haryana
MAIN OBJECTIVE OF THE COMPANY:-
Main objective set out in memorandum of association are
To manufacture, import, export of intravenous transfusion fluid and formation such as
dextrose, dextrose with Sodium chloride with many salts like ( normal saline, isolate,
Isolate G, etc. pharmaceutical parenteral preparation like aminophylline, adrenaline,
water for injection, chloride sulphate, Sodium bi-corbonate etc.
To carry on the business of deriving, formulating, purchasing preparing, processing,
missing, compounding, refining, marketing, distribution, selling and trading in
pharmaceutical, chemical, cosmetic, perfume, medicine and Drug of all kinds,
specification and description, and do so especially in respect of all kind of analgesics and
antipyretics.
To carry on the business of vialling, bottling, packing, repacking and processing of
capsules, syrups, tablets, Injectables, aerosols and ointment, bulk Drugs and chemicals.
6. In 2005 – Venus remedies successfully launches its brand “Ronem”
V.R announces strategic marketing tie up with M/s Cadila pharmaceutical ltd.
Themis medicate LTD enters into a strategic marketing tie up with Venus
remedies ltd.
Venus remedy has entered into strategic marketing agreement with Merck
Specialities Pvt.
A wholly owned subsidiary of Merck Ltd., Darmstadt, Germany, for its oncology
range of product.
In 2006 – Venus remedies ltd has informed that a company has been granted three
prestigious ISO certifications
V.R in- licenses product technology from USA
In 2007 – Venus remedies ltd has signed an arrangement with M/S Pharma match R&D
B.V LTD.
Company based at Amsterdam, Netherland for jointly preparing and marketing
an EU E-CTD dossier for a latest generation carbapenem Injectable
In 2008 - Venus facilities accredited with European certification.
V.R has informed that the company manufacturing facilities has been approved
by the G.F.T.O Syria for manufacturing and exporting its product to Syria,
European AMP accredited for Venus oncology facilities.
Company has successfully launched its fourth research product, a fixed dose
combination of cephalosporin with amino glycoside under the brand name of
“TOBRACEF” in domestic market for the first time globally.
In 2009 – product patent for “TOBRACEF” Granted in South Africa, another patent for
POTENTOX in South Africa.
In 2010 – Venus remedies ltd. A fast growing pharmaceutical company in the country,
has launched “MEBATIC”, A unique antibiotic combination in infusion form to cure
severe gastro intestinal (GL) Injections
Venus remedies receive GMP certification from Botswana
V.R ties up with IMTECH and Panjab university to develop Typhoid detection
kits
7. Company has received approval from the reserve bank of India for rollover for
FCCB USD 5mn, with YTM @4% maturity till Feb. 15,2015
Venus remedies Research blockbuster “Sulbactomax” get European Union
patent.
In 2011 – Venus remedies Anticancer “GEMCITABINE” GETS UK MHRA approval
Sulbactomax patent from Mexico strength Venus remedies presence in Latin
America.
V.R successfully completes phase first & second clinical trials of
TUMATREK(VRP 1620), cancer detection molecules
V.R ltd win gold medal for TROIS under DST –Lockheed martin India
innovation growth program 2011
V.R launches its patent research product “ACHNIL” in India.
V.R win India manufacturing award 2011
In 2012 – Venus product ACHNIL biospectrum product of the year 2012
Innovation solution for alleviating cancer
V.R introduced “ ready to use single vial Taxedol in India
Venus also introduced “TRIOS” that is a research based patent protected topical
nano-emulsion product in India
Company has won manufacturing Award for its world class manufacturing and
operational excellence at the “Industry 2.0 Manufacturing innovation conclave
2012
Venus won patent award in silver category
Other insight about the company:-
Venus is amongst the very few R&D led pharma companies in the world who is working
on to eradicate growing anti microbial resistance (AMR), recognized by WHO as being
severe medical crisis across the globe
Venus remedies limited is among the leading fixed – dosage Injectable manufacturers in
the world presently, the company has successfully made its presence in the market of
Phillipines, Thailand, Malaysia, Cambodia, Burma, Vietnam, sri lanka, Pakistan,
Bangladesh, Nepal, Ugamda, Kenya, Bostwana, Zimbabwe, Sudan, Mauritius, Yemen,
8. Iraq, Russia, Ukraine, Costarica, Venezula, Guatemala, Peru, Colombia, Syria, Togo,
Saudi Arbia and Iraq
Product- The company is engaged in manufacturing product catering various segments
such as oncology, cephalosporins, carbapenems and other specialties, intravenous
product, vials/lyophilized Injectable, per-filled syringes, Harmones, ampoules and
biological product
Venus remedies eyes Rs 1000 crore revenue by FY’17
The company currently has 25 product under its research and development portfolio of
which 13 are already commercialized
The margin for company’s R&D product are much higher than generic product we
expect around 40-45% margin out of all our R&D products
Company has obtained patents for its “Elores” antibiotic against superbugs from
Japanese authorities the product has so for received 46 patent from the developed world
this product already launched in India now its plan to launch in Japan
Venus remedies ltd. Said that all of its 9 facilities have received approval for GMP by
Ukraine, a Pic/S ( pharmaceutical inspection convention/ co- operation scheme ) nation,
this certification from national agency for food and Drug administration and control
(NAFDAC) Is an extended recognition for the company manufacturing facilities
Venus is the only company with a Ukrainian-GMP approval for large volume parenteral
for its Panchukla facility in India. It is present in the Ukrainnian market last 11 years and
is regularly exporting its various products in oncology, cephalosporin, carbapenem,
research product and other specialty Injectables.
MISSION – 2020:
1. To establish business as a marketing company driven by Research & Technology
2. To enhance customer base while sustain their loyalty and satisfaction.
3. To create brand recognition among doctors for Venus products, as solutions for unmet
medical needs.
4. To build ELORES as Rs.100 crore brand in India.
5. To secure our product presence in 60 countries around the world.
6. To monetize IP wealth of the company internationally.
9. 7. To make Venus as a debt free company.
8. To grow with a highly skilled, motivated, committed, productive and self progressive
team.
9. To ensure development of every department as a profit making enterprise.
10. To be a globally admired pharama company for ‘MADE IN VENUS’ quality and
innovations.
VISION:
1. We are in the business of preserving and improving human life through innovation.
2. We exist to provide value to our customer.
3. We ensure product quality, safety, reliability and excellence.
4. We manufacture medicines for patients, not for profits, profit follow.
5. We work with passion, commitment and enthusiasm.
6. We believe in hard work, productivity and continuous improvement.
7. We encourage & respect individual, initiative, ability and creativity to develop people as
the source of our strength.
8. We practice honesty, integrity and ethics in all aspects of business & strive to be best
corporate citizen.
9. We acknowledge our responsibilities towards our customers, our employees, the society
at large and last but not the least, our shareholders.
10. We shall build Venus as a nation.
10. INTRODUCTION
MEANING OF PAIN:
When people have inflammation it often hurts, they feel pain, stiffness,
discomfort, distress and perhaps agony, depending on the severity of it. Pain can be constant and
steady, in which case it is often referred to as an ache. Pain can be of a throbbing type, a
pulsating pain, or it can be a stabbing or pinching pain. Pain is a very individual experience and
the only person who can describe it properly is the one who is feeling it. Pain is an
uncomfortable feeling and/or an unpleasant sensation in the body. The presence of pain often is
an indication that something is wrong. Pain can appear suddenly or can come about slowly. Each
individual is the best judge of his or her own pain. Feelings of pain can range from mild and
occasional to severe and constant. Pain can be classified as acute pain or chronic pain.
TYPES OF PAIN:
ACUTE PAIN
Acute pain begins suddenly and is usually sharp in quality. It serves as a warning
of disease or a threat to the body. Acute pain might be caused by many events or circumstances,
including:
• Surgery
• Broken bones
• Dental work
• Burns or cuts
•Labor and childbirth
Acute pain might be mild and last just a moment, or it might be severe and last for weeks or
months. In most cases, acute pain does not last longer than six months, and it disappears when
the underlying cause of pain has been treated or has healed. Unrelieved acute pain, however,
might lead to chronic pain
11. CHRONIC PAIN
Chronic pain persists despite the fact that the injury has healed. Pain signals
remain active in the nervous system for weeks, months, or years. Physical effects include tense
muscles, limited mobility, a lack of energy, and changes in appetite. Emotional effects include
depression, anger, anxiety, and fear of re-injury. Such a fear might hinder a person's ability to
return to normal work or leisure activities. Common chronic pain complaints include:
• Headache
• Low back pain
• Cancer pain
• Arthritis pain
• Neurogenic pain (pain resulting from damage to nerves)
• Psychogenic pain (pain not due to past disease or injury or any visible sign of damage inside)
Chronic pain might have originated with an initial trauma/injury or infection, or there might be
an ongoing cause of pain. However, some people suffer chronic pain in the absence of any past
injury or evidence of body damage.
NOCICEPTIVE PAIN
Specific receptors are stimulated for us to feel this type of pain. These
receptors sense changes in temperature, vibration, stretch, and chemicals which damaged cells
release. "Nociceptive" means causing or reacting to pain - the cause of the pain comes from
outside the nervous system, and the nervous system reacts to it. "Non-nociceptive" means the
pain comes from within the nervous system itself.
SOMATIC PAIN
This is a kind of nociceptive pain. The sensation is felt in muscles, joints, bones,
ligaments, and on the skin. Musculo-skeletal pain is somatic pain. Pain receptors are sensitive to:
stretch in the muscles, vibration, temperature, as well as inflammation. When there is a lack of
oxygen there may be painful ischemic muscle cramps Somatic pain tends to be sharp and
localized - touching or moving the affected area will result in more severe pain.
12. VISCERAL PAIN
This is a kind of nociceptive pain. Pain is sensed deep down in the body, in the
internal organs and main body cavities, such as the heart, lungs, bowels, spleen, liver, kidneys,
bladder, uterus, and ovaries. The nociceptors (pain receptors) sense oxygen starvation
(ischemia), stretch, and inflammation. It is harder to localize visceral pain than somatic pain. The
pain is usually described as a deep ache. Cramping and colicky sensations are examples of
visceral pain. Inflammation primarily causes pain because the swelling pushes against the
sensitive nerve endings, which send pain signals to the brain. Nerve endings send pain signals to
the brain all day long; however, it learns to ignore most of them, unless pressure against the
nerve endings increases. Other biochemical processes also occur during inflammation which
affect how nerves behave, and cause pain.
13. OBJECTIVE OF THE STUDY:
To study the current scenario of Injectable in pain management.
To study the doctor prescription pattern.
To study the severity of pain with which patients come.
To study the preferable therapy given to them.
SCOPE OF THE PROJECT:
The study made and data collected is useful for the future planning of the company.
The study is further important to the organization in tuning the company’s strategies as
per local market expectation.
The study is helpful to the organization for to understand current market situation,
strategy and policies adopted by competitor.
14. RESEARCH METHODOLOGY
The value of any systematic research lies in its methodology which is a way to systematically
solve research problems. Methodology helps the investigator to conduct the project study in a
prescribed manner.
METHOD OF SAMPLING
“Sampling can be defined as the process of selecting a representative portion of the population
understudy for analysis” sampling is in which only a portion and not the whole population is
surveyed. It was selected by a convenience sampling method.
METHODS OF DATA COLLECTION AND SOURCES
After the research objectives the researcher has to collect the needed information. In data
collection methods, one should know about the variety and sources of data which may yield the
derived results, there are two sources of data,
• Primary data
• Secondary data
PRIMARY DATA
Primary data is those data which is collected at first hand either by the researcher himself or by
someone else especially for the purpose of study.
SOURCES OF PRIMARY DATA
Survey sheet
Questionnaires
15. SECONDARY DATA
In the hand of the researcher the data became secondary if was gathered earlier for some other
purposes from the following.
SOURCES OF SECONDARY DATA
Journals
Brochures
POPULATION
It is the aggregate of all the elements defined before selection of sample. For this analysis
researcher, selected various cities Mohali, Chandigarh, Nangal to Anandpur sahib chemist shops
and hospitals.
SAMPLE SIZE
For Survey purpose researcher selected 75 chemist shops in which 15 chemist shops from
Chandigarh area and 35 from Nangal and Anandpur Sahib Area and 25 from Mohali area as
sample size. The researcher selected 50 Doctors as a sample from various Areas for getting a
information to fulfill the objective of the study. Out of 50 doctors 25 doctors from Nangal &
Anandpur Sahib Area and 25 doctors from Chandigarh & Mohali Area.
LIMITATION OF THE STUDY
1. As the data is collected through questionnaire, respondents may answer the questions with a
bias.
2. The sample survey method has certain limitations
3. The standard of answering the questions by the respondents was not that high as excepted.
4. The study is undertaken as a part of the project work, for the academic purpose only.
5. The result may be depended on the answer received from respondent.
16. DATA ANALYSIS AND INTERPRETATION
The researcher held thorough interviews with 75 chemist Shops of various places in Chandigarh,
Mohali, Nangal & Anandpur Sahib for the purpose of study. The respondents were taken on the
basis random sampling. The study conducted by formulating Survey sheet so as to accept and
reject responses accordingly. The data collected was subjected to percentage-wise analysis and
presented in tabular form. The data collection, analysis and interpretation focus on assessing the
current scenario of Injectable in pain management. Tabulation was held as per, number wise and
percentage wise.
I.CURRENT SCENARIO OF INJECTABLE IN PAIN MANAGEMENT
(MOHALI AREA)
Table no.1: Commonly used Injectable in Mohali
MOHALI AREA
Brand Name Ingredient Company Name No. of
Chem Sale
Total
Chem
%age
Inj. Veveron Diclofenac Sodium Novertics 18 24 75
Inj. Tramadol Tramadol
Hydrochloride
Cadila 15 24 63
Inj. Buscopan Hyscine Butlybromide Zcedruge 11 24 46
Inj. Justin Diclofenac Sodium Neon 8 24 33
Inj. Dynatory Diclofenac Sodium Trioka 7 24 29
Inj. Fenak Diclofenac Sodium Ranbaxy 6 24 25
Inj. Alfasil PCM + Tramadol
Sodium
Johnson &
Johnson
6 24 25
Inj. Alpyrin Aspirin Loncorn 5 24 21
Inj. Zerodol Acecelofenac Sodium Ipca 5 24 21
Inj, Tramazac Tramadol HCl Zydus 4 24 17
Inj. Mypar Paracetamol Morphen 3 24 13
Inj. Dolonex Piroxicam Pfizer 3 24 13
Inj. Flexilor Lornaxicam Glenmark 3 24 13
Inj. Decasone Dexamethasone
Sodium phosphate
Jackson 2 24 8
17. Figure no.1: Commonly used Injectable in Mohali
INTERPRETATION:
` Voveron is commonly used Injectable in Pain Management as 75%
chemists have stock of it. 63% of chemist shops have a stock of Tramadol Injection. Only 8%
chemist shops have a stock of the Decasone injection. The above data shows that Voveron
Injection had a highest sale in the Mohali area as compare to other pain killer Injectable
0
10
20
30
40
50
60
70
80 75
63
46
33
29
25 25
21 21
17
13 13 13
8
%age
BRAND NAME
18. CURRENT SCENARIO OF INJECTABLE IN PAIN MANAGEMENT
(CHANDIGARH AREA)
Table no.2: Commonly used Injectable in Chandigarh
Chandigarh Area
Brand
Name
Ingredient Company
Name
No. of
Chem Sale
Total
Chem
%age
Inj. Voveran Diclofenac Sodium Novertics 12 15 80
inj.Tramadol Tramadol
Hydrochloride
Cadila 10 15 67
Inj. Buscopan Hyscine Butlybromide Zcedruge 8 15 53
Inj. Justin Diclofenac Sodium Neon 8 15 53
Inj. Decasone Dexamethasone
Sodium phosphate
Jackson 7 15 47
Inj. Dynatory Diclofenac Sodium Triokaa 6 15 40
Inj.Defenac Diclofenac Sodium Lupin 6 15 40
Inj. Dynapar
AQ
Diclofenac Sodium Triokaa 6 15 40
Inj.Nise Nimuslide Dr.Reddy Lab.
Ltd.
5 15 33
Inj. Zerodol Acecelofenac Sodium Ipca 5 15 33
Inj.Fenak Diclofenac Sodium Ranbaxy 4 15 27
Inj. Dolonex Piroxicam Pfizer 4 15 27
Inj. Syn-D Diclofenc Sodium Synlar 3 15 20
Inj. Hyocimax Hyoscyamine Zydus 3 15 20
19. Figure no.2: Commonly used Injectable in Chandigarh
INTERPRETATION:
` Voveron is commonly used Injectable in pain management as 80%
chemists have stock of it. 67% of chemist shops have a stock of Ttramadol Injections. In
Chandigarh chemist shops 47% of chemist shops have a stock of Decasone Injection.33% of
chemist shops sales Zerodol Injection in Chandigarh area. Only 27% chemist shops sales
Dolonex Injection.
0
10
20
30
40
50
60
70
80
80
67
53 53
47
40 40 40
33 33
27 27
20 20
BRAND NAME
20. CURRENT SCENARIO OF INJECTABLE IN PAIN MANAGEMENT
(NANGAL TO ANANDPUR SAHIB)
Table no.2: Commonly used Injectable in Nangal to Anandpur Sahib
NANGAL AREA
Brand Name Ingredient Company
Name
No. of Chem
Sale
Total
Chem
%age
inj. Voveran Diclofenac Sodium Novartis 32 35 91
inj. Dolonex piroxicam Sodium Pfizer 21 35 60
inj. Ketanov Ketrofenac sun pharma 15 35 43
inj.Buscopan Hyscine Butlybromide Cadila 11 35 31
inj. Zerodol Acecelofenac Ipca 10 35 29
inj. Fenak plus Diclofenac Sodium Ranbaxy 9 35 26
inj. Brofenac Diclofenac Sodium Martin 9 35 26
inj.Nobel Spas Dicyclomine+ Diclofenac
Sodium
Mankind 6 35 17
Inj. Flexilor Lornaxicam Glenmark 6 35 17
inj.Justin Diclofenac Sodium Neon 5 35 14
inj. Contramol Tramadol Hydrochloride pfizer 4 35 11
inj. Paramol PCM jackson 4 35 11
inj. Doraten Drotevarine Martin& haris 4 35 11
Inj.Febrnil PCM Svizera 4 35 11
Inj.Anafortan Camylofim Abbott 4 35 11
inj.esgipyrim Diclofenac Sodium Abbott 3 35 9
inj. Defenac Diclofenac Sodium Lupin 3 35 9
Inj. Decasone Dexamethasone Sodium
phosphate
Jackson 3 35 9
Inj.Nelfy Nulputhine Glenmark 3 35 9
inj. Tramadol Tramadol Hydrochloride johnson&
johnson
2 35 6
inj. Qmal Acecelofenac Qure biotee 2 35 6
Inj. Drotikind Drotevarine hydrochoride mankind 2 35 6
21. Figure no.3: Commonly used Injectable in Nangal to Anandpur Sahib
INTERPRETATION:
` Voveron is commonly used Injectable in pain management as 91%
chemists have stock of it.60% of chemist shops have a stock of Dolonex Injection. The above
data express that 43% of chemist shops sale Ketanov Injection. Only 6% of chemist shops sales
Tramadol Injections and 6% of chemist shops store Drotikind Injection.
0
10
20
30
40
50
60
70
80
90
100
inj.Voveran
inj.Dolonex
inj.Ketanov
inj.Buscopan
inj.Zerodol
inj.Fenakplus
inj.Brofenac
inj.NobelSpas
Inj.Flexilor
inj.Justin
inj.Contramol
inj.Paramol
inj.Doraten
Inj.Febrnil
Inj.Anafortan
inj.esgipyrim
inj.Defenac
Inj.Decasone
Inj.Nelfy
inj.Tramadol
inj.Qmal
Inj.Drotikind
91
60
43
31
29
26 26
17 17
14 11 11 11 11 11
9 9 9 9
6 6 6
%age
BRAND NAME
22. II. DOCTORS PRESCRIPTION PATTERN:
Table no.4: Analysis Doctor Prescription Pattern in Mohali
MOHALI AREA
S.no. Ingredient %age
1 Diclofenac Sodium 100
2 Tramadol Hydrochloride 79
3 Hyscine Butlybromide 46
4 PCM + Tramadol Sodium 25
5 Aspirin 21
6 Acecelofenac Sodium 21
7 Paracetamol 13
8 Piroxicam 13
9 Lornaxicam 13
10 Dexamethasone Sodium phosphate 8
Figure no.4: Analysis Doctor Prescription Pattern in Mohali
INTERPRETATION:
Diclofenac Sodium is preferable therapy for pain management. As 100%
doctor prefer this Drug.79% doctor choice Ttramadol hydrochloride for pain patients.21%
Acecelofenac Sodium Injection prescribed by doctors for patients.
0
50
100
100
79
46
25 21 21
13 13 13 8
%age
INGREDIENT
23. Table no.5: Analysis Doctor Prescription Pattern in Chandigarh
CHANDIGARH AREA
S.no Ingredient Chem. Sale Total Chem %age
1 Diclofenac Sodium 15 15 100
2 Tramadol Hydrochloride 10 15 67
4 Hyscine Butlybromide 8 15 53
6 Dexamethasone Sodium phosphate 7 15 47
3 Nimuslide 5 15 33
8 Acecelofenac Sodium 5 15 33
7 Piroxicam 4 15 27
5 Hyoscyamine 3 15 20
Figure no.5: Analysis Doctor Prescription Pattern in Chandigarh
INTERPRETATION:
Diclofenac Sodium is preferable therapy for pain management. As 100%
doctor prefer this Drug. Dexamethasone Sodium phosphate Drug prefer 47% doctor for pain.
0
20
40
60
80
100
100
67
53
47
33 33
27
20
%age
INGREDIENT
24. Table no.6: Analysis Doctor Prescription Pattern in Nangal
NANGAL AREA
S.no. Ingredients No.of Chem Sale
Total
Chem.
%age
1 Diclofenac Sodium 35 35 100
2 piroxicam Sodium 21 35 60
3 Ketrofenac 15 35 43
4 Acecelofenac 12 35 34
5 Hyscine Butlybromide 11 35 31
6 PCM 8 35 23
7 Dicyclomine+ Diclofenac Sodium 6 35 17
8 Lornaxicam 6 35 17
9 Tramadol Hydrochloride 6 35 17
10 Drotevarine 4 35 11
12 Camylofim 4 35 11
13 Dexamethasone Sodium phosphate 3 35 9
14 Nulputhine 3 35 9
15 Drotevarine hydrochoride 2 35 6
Figure no.6: Analysis Doctor Prescription Pattern in Nangal
INTERPRETATION:
Diclofenac Sodium is preferable therapy for pain management. As 100%
doctor prefer this Drug.60% piroxicam Sodium Injectable prefer by doctors. 34% Acecelofenac
Sodium Drug prescribed by doctors for pain patients. Camylofim Drug prefer by doctor only 11%.
0
50
100
100
60
43
34 31
23 17 17 17 11 11 9 9 6
%age
INGREDIENT
25. III. THE SEVERITY OF PAIN WITH WHICH PATIENTS COME
Q.1: Number of patient with pain?
Table no 7: Analysis of number of patients with pain for Nangal & Anandpur Sahib Area
Figure no.7: Analysis of number of patients with pain for Nangal & Anandpur Sahib Area
INTERPRETATION:
Out of 25 doctors 15 doctors said that they have approximately 75 patients
suffer from pain in OPD. 7 doctors said that they have less than 50 patients suffer from pain.
Only 3 doctors check pain patients in OPD less than 10.
0%
60%
28%
12%
<100 >75 >50 >10
NUMBEROF PATIENTS
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
<100 0 25 0
>75 15 25 60
>50 7 25 28
>10 3 25 12
26. Table no 8: Analysis of number of patients with pain for Chandigarh & Mohali Area
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
<100 1 25 4
>75 13 25 52
>50 9 25 36
>10 2 25 8
Figure no 8: Analysis of number of patients with pain for Chandigarh & Mohali Area
INTERPRETATION:
Out of 25 doctors 13 doctors said that they have a approximately 75
patients suffer from pain in OPD. 9 doctors said that they have less than 50 patients suffer from
pain. Only 2 doctors check pain patients in OPD less than 10.
4%
52%
36%
8%
NUMBER OF PATIENTS
<100 >75 >50 >10
27. Q.2 Number of patient with Acute pain?
Table no 9: Analysis of number of patients with Acute pain for Nangal & Anandpur Sahib
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
>75 0 25 0
>50 13 25 52
>20 6 25 24
>10 6 25 24
Figure no.9: Analysis of number of patients with Acute pain for Nangal & Anandpur Sahib
INTERPRETATION:
13 doctors out of 25 doctors treat less than 50 patients of acute pain.6
doctors said that they check less than 20 patients of acute pain in OPD.
0%
52%
24%
24%
>75 >50 >20 >10
NUMBER OF PATIENTS
28. Table no 10: Analysis of number of patients with Acute pain for Chandigarh & Mohali
Area
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
>75 0 25 0
>50 8 25 32
>20 10 25 40
>10 7 25 28
Figure no 10: Analysis of number of patients with Acute pain for Chandigarh & Mohali
Area
INTERPRETATION:
10 doctor’s respondent that they have less than 20 patients those suffer
from acute pain.8 doctors respondent that they have less than 50 patients in a OPD whose suffer
from acute pain.7 doctors respondent that they have less than 10 patient of acute pain.
0%
32%
40%
28%
>75 >50 >20 >10
NUMBER OF PATIENTS
29. Q.3 Number of patients with Chronic Pain?
Table no 11: Analysis of number of patients with Chronic pain for Nangal & Anandpur
Sahib
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
>75 4 25 16
>50 12 25 48
>20 7 25 28
>10 2 25 8
Figure no 11: Analysis of number of patients with Chronic pain for Nangal & Anandpur
Sahib
INTERPRETATION:
12 doctor’s respondent that they have less than 50 patients those suffer
from chronic pain.7 doctor’s respondent that they have less than 20 patients in a OPD whose
suffer from chronic pain.4 doctors respondent that they have less than 75 patient of chronic pain.
2 doctor’s respondent that they have less than 10 patients of chronic pain.
16%
48%
28%
8%
>75 >50 >20 >10
NUMBEROF PATIENTS
30. Table no 12: Analysis of number of patients with Chronic pain for Chandigarh & Mohali
Area
Figure no 12: Analysis of number of patients with Chronic pain for Chandigarh & Mohali
Area
INTERPRETATION:
10 doctor’s respondent that they have less than 20 patients those suffer
from chronic pain.9 doctors respondent that they have less than 50 patients in a OPD whose
suffer from chronic pain.5 doctors respondent that they have less than 75 patients of chronic pain
20%
36%
40%
4%
>75 >50 >20 >10
NUMBER OF PATIENTS
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
>75 5 25 20
>50 9 25 40
>20 10 25 36
>10 1 25 4
31. IV.PREFERABLE THERAPY GIVEN TO THEM:
Q.4 Treatment/ Therapy opted for severe acute pain?
Table no 13: Analysis the therapy for severe acute pain for Nangal & Anandpur Sahib
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
ORAL 2 25 8
INJECTION 23 25 92
Figure no 13: Analysis the therapy for severe acute pain for Nangal & Anandpur Sahib
INTERPRETATION:
23 doctor’s respondent that they give Injection therapy for severe acute
pain patients. 2 doctor’s respondent that they give oral therapy to severe acute pain patients.
8%
92%
ORAL INJECTION
32. Table no 14: Analysis the therapy for severe acute pain for Chandigarh & Mohali Area
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
ORAL 3 25 12
INJECTION 22 25 88
Figure no 14: Analysis the therapy for severe acute pain for Chandigarh & Mohali Area
INTERPRETATION:
22 doctor’s out of 25 doctor’s respondent that they give Injection therapy
for severe acute pain patients. 3 doctor’s out of 25 doctor’s respondent that they give oral therapy
to severe acute pain patients.
12%
88%
ORAL INJECTION
33. Q.5 First Preference of molecule severe Acute pain?
Table no 15: Analysis the Preference molecule for severe acute pain for Nangal &
Anandpur Sahib
Figure no 15: Analysis the Preference molecule for severe acute pain for Nangal &
Anandpur Sahib
INTERPRETATION:
20 doctor’s out of 25 doctor’s used NSAIDs for the first therapy of severe
acute pain patients. 4 doctors’s used morphine for the severe acute pain.1 doctor used steroid for
the severe acute pain patients.
16%
80%
4%
Morphine NSAIDs Steroid
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
Morphine 4 25 16
NSAIDs 20 25 80
Steroid 1 25 4
34. Table no 16: Analysis the Preference molecule for severe acute pain for Chandigarh &
Mohali Area
Table no 16: Analysis the Preference molecule for severe acute pain for Chandigarh &
Mohali Area
INTERPRETATION:
23 doctor’s out of 25 doctor’s used NSAIDs for the first therapy of severe
acute pain patients. 1 doctor’s used morphine for the severe acute pain.1 doctor used steroid for
the severe acute pain patients.
4%
92%
4%
Morphine NSAIDs Steroid
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
Morphine 1 25 4
NSAIDs 23 25 92
Steroid 1 25 4
35. Q.6 Type of Injectable NSAIDs prescribed in Acute Pain?
Table no 17: Analysis the Injectable NSAIDs prescribed in acute pain for Nangal &
Anandpur Sahib Area
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
Diclofenac 16 25 75
Ketorolac 6 25 15
Acecelofenac 3 25 10
Table no 17: Analysis the injectable NSAIDs prescribed in acute pain for Nangal &
Anandpur Sahib Area
INTERPRETATION:
15 doctors prescribed Diclofenac Sodium for acute pain patients. 3
doctors prescribed Ketorolac for severe acute pain patients. 2 doctors prescribed Acecelofenac
Sodium for the acute pain patients.
75%
15%
10%
Diclofenac ketorolac Aceclofenac
36. Table no 18: Analysis the Injectable NSAIDs prescribed in acute pain for Chandigarh &
Mohali Area
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
Diclofenac 13 25 52
Ketorolac 5 25 20
Aceclofenac 7 25 28
Table no 18: Analysis the injectable NSAIDs prescribed in acute pain for Chandigarh &
Mohali Area
INTERPRETATION:
.13 doctors prescribed Diclofenac Sodium for acute pain patients. 7
doctors prescribed Acecelofenac Sodium for the acute pain patients. 5 doctors prescribed
Ketorolac for severe acute pain patients.
52%
20%
28%
Diclofenac ketorolac Aceclofenac
37. Q.7 Preference of pain killer?
Table no 19: Analysis the Preference of pain killer for Nangal & Anandpur Sahib Area
Nangal & Anandpur Sahib Area
Category Number of
respondents
Total respondents %age
Short acting 18 25 72
Long Acting 7 25 28
Figure no 19: Analysis the Preference of pain killer for Nangal & Anandpur Sahib Area
INTERPRETATION:
Out of 25 doctors 18 doctors believes in short acting Injectable.7 doctors
believes in long acting Injectable.
72%
28%
Short acting Long Acting
38. Table no 20: Analysis the Preference of pain killer for Chandigarh & Mohali Area
Chandigarh & Mohali Area
Category Number of
respondents
Total respondents %age
Short acting 16 25 64
Long Acting 9 25 36
Figure no 20: Analysis the Preference of pain killer for Chandigarh & Mohali Area
INTERPRETATION:
Out of 25 doctors 16 doctors believes in short acting Injectable.9 doctors
believes in long acting Injectable.
64%
36%
Short acting Long Acting
42. Figure 22: Analysis of Prescription Pattern of Injectable in Pain Management
INTERPRETATION:
Almost 100% chemist shops sales Diclofenac Sodium Drug for the pain
patients. 47% of chemist shops have a stock of Tramadol Hydrochloride Drug.30% of chemist sale
Acecelofenac Drug to pain patient.
0
10
20
30
40
50
60
70
80
90
100
3 4 4 4 5 5 7 7 8 8
11 12
16
20
30
38
41
47
100
INGREDIENT
%age
43. VI. CLASS OF PAIN PATIENTS AND PREFERABLE THERAPY GIVEN TO THEM
Q.1: Number of patient with pain?
Table no 23: Analysis of number of patients
Figure no.23: Analysis of number of patients with pain
INTERPRETATION:
Almost 56% doctor’s said that they have approximately 75 patients suffer
from pain in OPD. 32% doctor’s said that they check less than 20 patients of pain in OPD.
2%
56%
32%
10%
<100 >75 >50 >10
NUMBEROF PATIENTS
Nangal & Anandpur
Sahib Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
%age
<100 0 25 1 25 1 50 2
>75 15 25 13 25 28 50 56
>50 7 25 9 25 16 50 32
>10 3 25 2 25 5 50 10
44. Q.2 Number of patient with Acute pain?
Table no 24: Analysis of number of patients with Acute pain
Figure no.24: Analysis of number of patients with Acute pain
INTERPRETATION:
42% of doctors treat less than 50 patients of acute pain in OPD. 32% of
doctor’s check less than 20 patients in OPD those suffer from acute pain.
0%
42%
32%
26%
>75 >50 >20 >10
NUMBEROF PATIENTS
Nangal & Anandpur Sahib
Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
%age
>75 0 25 0 25 0 50 0
>50 13 25 8 25 21 50 42
>20 6 25 10 25 16 50 32
>10 6 25 7 25 13 50 26
45. Q.3 Number of patients with Chronic Pain?
Table no25: Analysis of number of patients with Chronic pain
Figure no 25: Analysis of number of patients with Chronic pain
INTERPRETATION:
42% of doctors treat less than 50 patients of chronic pain in OPD. 34% of doctors
check less than 20 patients of chronic pain. 18% of doctors treat less than 10 patients of chronic
pain.
18%
42%
34%
6%
>75 >50 >20 >10
NUMBER OF PATIENTS
Nangal & Anandpur
Sahib Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
%age
>75 4 25 5 25 9 50 18
>50 12 25 9 25 21 50 42
>20 7 25 10 25 17 50 34
>10 2 25 1 25 3 50 6
46. Q.4 Treatment/ Therapy opted for severe acute pain?
Table no 26: Analysis the therapy for severe acute pain
Figure no 26: Analysis the therapy for severe acute pain
INTERPRETATION:
90% of doctors gives Injection therapy for severe acute pain patients. Only
10% doctors gives oral therapy to severe acute pain patients.
10%
90%
ORAL INJECTION
Nangal & Anandpur Sahib
Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
%age
ORAL 2 25 3 25 5 50 10
INJECT-
ION
23 25 22 25 45 50 90
47. Q.5 First Preference of molecule severe Acute pain?
Table no 27: Analysis the Preference molecule for severe acute pain
Figure no 27: Analysis the Preference molecule for severe acute pain
INTERPRETATION:
Almost 86% of doctors used NSAIDs molecule for severe acute pain
patients.10% of doctors used Morphine at the time of treatment of severe acute pain patients. 4%
doctors used steroid for the severe acute pain patients.
10%
86%
4%
Morphine NSAIDs Steroid
Nangal & Anandpur Sahib
Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
% age
Morphine 4 25 1 25 5 50 10
NSAIDs 20 25 23 25 43 50 86
Steroid 1 25 1 25 2 50 4
48. Q.6 Type of Injectable NSAIDs prescribed in Acute Pain?
Table no 28: Analysis the Injectable NSAIDs prescribed in acute pain
Table no 28: Analysis the Injectable NSAIDs prescribed in acute pain
INTERPRETATION:
58% of doctors prescribed diclofenac Sodium NSAIDs for the acute pain
patients. 22% of doctors gives Ketorolac NSAIDs Injectable for the acute pain patients. Only
20% of doctors prefer Aceclofenac NSAIDs for acute pain patients.
58%22%
20%
Diclofenac ketorolac Acecelofenac
Nangal & Anandpur Sahib
Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
% age
Diclofena
c
16 25 13 25 29 50 58
Ketorolac 6 25 5 25 11 50 22
Aceclofe-
nac
3 25 7 25 10 50 20
49. Q.7 Preference of pain killer?
Table no 29: Analysis the Preference of pain killer
Figure no 29: Analysis the Preference of pain killer
INTERPRETATION:
68% prefer short acting Injectable for pain patients. 32% of doctors
believe in prescribed long acting Injectable for the acute pain patients.
68%
32%
Short acting Long Acting
Nangal & Anandpur
Sahib Area
Chandigarh & Mohali
Area
TOTAL
Category Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
Number of
respondents
Total
respondents
% age
Short acting 18 25 16 25 34 50 68
Long
Acting
7 25 9 25 16 50 32
50. CONCLUSION
The study conducted so far on “The Scope of Long acting Injectable pain preparation and survey
of current prescription pattern of Injectables in Pain Management” reveals following
conclusions:
1. Chemist survey data analysis, it is found that Voveron Injection commonly used to treat pain
in pain management as 84% of chemists have stock of it.
2. From doctor prescription pattern analysis, it is found that generally doctor prefer Diclofenac
Sodium Drug in Pain Management.
3. From the questionnaire answer, it is found that more than 50% of doctors have less than 75
patients of pain in their daily OPD.42% of doctors treat less than 50 of acute pain patients
and 42% of doctors check less than 50 patients of chronic pain in their OPD. 90% of doctors
prefer Injectable to treat severe acute pain patients. Generally the choice of molecule is
NSAIDs and mainly short acting Diclofenac Injections are preferred to treat Veacute pain
patients.
4. Venus remedies Acecelofenac Injection under Brand name “ACHNIL” can be targeted
against Diclofenac Injection as single dose where to control pain Diclofenac Injection needs
2-3 times a day. Achnil ( Acecelofenac 150mg/3ml) is long acting and can relief up to 24
hours.
5. Survey confirms the need of an injection that is long acting and good pain reliever.
